Long-Term Efficacy of a Treat-and-Extend Regimen with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: An Open-Label 12-Month Extension to the CANTREAT Study

• Main Authors: Baker, J. (Author), CANTREAT Investigators (Author), Galic, I.J (Author), Greve, M. (Author), Kertes, P.J (Author), Sheidow, T. (Author), Williams, G. (Author)
• Format: Article
• Language: English
• Published: NLM (Medline) 2022
• Subjects: angiogenesis inhibitor; Angiogenesis Inhibitors; Best-corrected visual acuity; human; Humans; Injections; intravitreal drug administration; Intravitreal Injections; macular degeneration; Macular Degeneration; Neovascular age-related macular degeneration; optical coherence tomography; ranibizumab; Ranibizumab; Tomography, Optical Coherence; Treat and extend; treatment outcome; Treatment Outcome; Vascular Endothelial Growth Factor A; vasculotropin A; visual acuity; Visual Acuity; wet macular degeneration; Wet Macular Degeneration
• Online Access: View Fulltext in Publisher

 INTRODUCTION: The objective of this study is to assess the long-term effectiveness of a treat-and-extend (T&E) anti-vascular endothelial growth factor regimen in patients with neovascular age-related macular degeneration who remain on T&E and those switched from once-monthly (OM) dosing to T&E (OM-T&E). METHODS: In this 12-month extension of the 2-year CANTREAT study, patients received intravitreal ranibizumab 0.5 mg in a T&E regimen. Main outcome measures included mean change in best-corrected visual acuity (BCVA) from baseline and from month 24 to month 36; percentages of patients who gained ≥5, ≥10, or ≥15 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters or lost ≥5, ≥10, or ≥15 letters from baseline and from month 24 to month 36; and number of injections administered from baseline and from month 24 to month 36 for both groups. RESULTS: Of the 139 patients (73 T&E, 66 OM-T&E) in the extension, 121 (68 T&E, 53 OM-T&E) completed 36 months. Mean (standard deviation [SD]) BCVA changes from baseline to the extension last visit (month 33-36) were +6.6 (11.4) letters in the T&E group and +4.8 (14.3) letters in the OM-T&E group, representing maintenance of 24-month gains. The mean (SD) numbers of injections during the extension were 7.3 (2.7) for T&E and 7.1 (2.8) for OM-T&E. DISCUSSION/CONCLUSION: These findings suggest that after 36 months of treatment, the mean BCVA improvement achieved at 24 months is maintained for both the patients exclusively treated with the T&E regimen and those that switched to T&E after 24 months in the OM regimen. © 2021 The Author(s). Published by S. Karger AG, Basel.